ArticleThe Journal of molecular diagnostics : JMD2010
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
Article in The Journal of molecular diagnostics : JMD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 96 citations in OpenAlex.
- Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.Molecular diagnosis & therapy · 2019Article
- Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.Histopathology · 2019Article
- Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.BMC cancer · 2017Article
- Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.The Journal of molecular diagnostics : JMD · 2016Article
- Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective.BioMed research international · 2016Review
- Article
- Quality assurance in clinical trials--the role of pathology.Virchows Archiv : an international journal of pathology · 2016Review
- Development of a gLCR-based KRAS mutation detection approach and its comparison with other screening methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.Diagnostic pathology · 2015Article
- Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.European journal of nuclear medicine and molecular imaging · 2014Article
- Article
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.Nature medicine · 2014Article
- Article
- Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Cancer gene therapy · 2013Review
- Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.Cancer medicine · 2013Article
- KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Virchows Archiv : an international journal of pathology · 2013Article
- Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.Journal of clinical pathology · 2012Article
- A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.Journal of experimental & clinical cancer research : CR · 2012Article
- Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- KRAS Testing: A Tool for the Implementation of Personalized Medicine.Genes & cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS mutation testing before anti-epidermal growth factor receptor therapy of metastatic colorectal cancer has become mandatory in Europe. However, considerable uncertainty exists as to which methods for detection can be applied in a reproducible and economically sound manner in the routine diagnostic setting. To answer this question, we examined 263 consecutive routine paraffin slide specimens. Genomic DNA was extracted from microdissected tumor tissue. The DNA was analyzed prospectively by Sanger sequencing and array analysis as well as retrospectively by melting curve analysis and pyrosequencing; the results were correlated to tissue characteristics. The methods were then compared regarding the reported results, costs, and working times. Approximately 40% of specimens contained KRAS mutations, and the different methods reported concordant results (kappa values >0.9). Specimens harboring fewer than 10% tumor cells showed lower mutation rates regardless of the method used, and histoanatomical variables had no influence on the frequency of the mutations. Costs per assay were higher for array analysis and melting curve analysis when compared with the direct sequencing methods. However, for sequencing methods equipment costs were much higher. In conclusion, Sanger sequencing, array analysis, melting curve analysis, and pyrosequencing were equally effective for routine diagnostic KRAS mutation analysis; however, interpretation of mutation results in conjunction with histomorphologic tissue review and on slide tumor tissue dissection is required for accurate diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.